No quarterly revenue total was found in ALZAMEND NEURO, INC.'s SEC filings.
Alzamend Neuro, Inc. (ALZN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-3.03M
-12.0% vs year-ago quarter
Operating cash flow
$-1.14M
+51.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.68
+46.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
4.83M
+53.7% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALZN (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1677077
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jul 31, 2026 |
Q4 FY2026 Apr 30, 2026 |
Q3 FY2026 Jan 31, 2026 |
Q2 FY2026 Oct 31, 2025 |
Q1 FY2026 Jul 31, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.0M | -$2.9M | -$2.2M | -$998,109 | -$2.7M |
| Net income | -$3.0M | -$2.9M | -$2.2M | -$1.0M | -$2.7M |
| Diluted EPS | -$0.68 | -$0.72 | -$0.58 | -$0.30 | -$1.28 |
| Operating cash flow | -$1.1M | -$2.8M | -$1.7M | -$1.2M | -$2.4M |
| Total assets | $8.5M | $2.1M | $4.0M | $5.1M | $6.3M |
| Total liabilities | $2.7M | $1.3M | $1.9M | $717,488 | $983,311 |
| Stockholders' equity | $5.8M | $733,211 | $2.2M | $4.4M | $5.3M |
| Cash and investments | $7.6M | $710,689 | $2.7M | $4.4M | $5.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Sep 10, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Material agreement, Listing notice, Unregistered share sale, Bylaw or fiscal year change
|
Aug 3, 2026 | Aug 3, 2026 |
| 10-K | Annual report | Jul 22, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 21, 2026 | Jul 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Apr 17, 2026 | Apr 17, 2026 |
All 397 Alzamend Neuro, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.